A phase III, prospective study to evaluate the safety and efficacy of ALN-PCSsc in patients with hypercholesterolemia

Trial Profile

A phase III, prospective study to evaluate the safety and efficacy of ALN-PCSsc in patients with hypercholesterolemia

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ORION-4
  • Sponsors The Medicines Company
  • Most Recent Events

    • 09 Aug 2017 According to an Alnylam Pharmaceuticals media release, the Company intends to initiate this trial in late-2017.
    • 26 Apr 2017 According to The Medicines Company media release, this trial is a part of the phase III program for inclisiran, which is designed to support the NDA submission anticipated at or around the end of 2019. The Phase III program will comprise clinical trials in subjects with atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH), and will collectively enroll approximately 3,000 subjects randomized to treatment with inclisiran (1,500) or placebo (1,500).
    • 08 Jan 2017 According to The Medicines Company media release, company expects discussion with regulatory authorities regarding the Phase 3 development plan for inclisiran prior to the initiation of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top